Please assess the completion status of the following clinical trial:

Trial Title: Prospective Validation Study for the Proprietary Rectal and Anal Cancer Protein Expression Assays

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~1. Subjects with histologically confirmed stage II and III rectal adenocarcinoma or subjects with histologically confirmed stage II and III anal SCC~2. Subjects greater than 18 years of age.~3. Subjects who will undergo prescribed neoadjuvant chemotherapy and/or radiotherapy and have surgical resection prior to further treatment or pathologic confirmation of treatment response using endoscopy or ultrasound.~4. Subjects with:~   * twenty (20) unstained sections on charged slides available from tumor block (FFPE) used for the diagnosis of rectal/anal carcinoma or adjacent to this block (pre-neoadjuvant biopsy sample); and~  * four (4) unstained slides available from post-chemoradiation surgery to allow for blinded pathology review and assessment of pathCR, partial CR, or exCTRT. Slides from surgical resection are not necessary in cases with documented post-surgical determination of response by ultrasound or endoscopy.~5. Subjects willing to complete study follow up for outcomes.~6. Subjects from who informed consent can be obtained.~Exclusion Criteria:~1. Subjects with carcinoma in situ or Stage I rectal/anal carcinoma.~2. Subjects with Stage IV rectal/anal carcinoma.~3. Subjects with diagnosis of other malignant tumors with the exception of non-melanoma skin cancers cured by resection only.~4. Subjects that have received prior chest or upper abdomen radiotherapy and/or system chemotherapy within the past 5 years~5. Subjects who are unwilling to complete study follow up~6. Employees and family members of Investigator

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).